Method of 5ъ-deoxy-5-fluorocytidine synthesis

专利摘要:
The novel 5'-deoxy-5-fluorocytidine derivatives of formula <IMAGE> (I) wherein R1, R2 and R3 are hydrogen or an easily hydrolyzable radical under physiological conditions, with the proviso that, at least one or R1, R2 and R3 is an easily hydrolyzable radical under physiological conditions, as well as hydrates of solvates of these compounds have antitumor properties. They can be prepared from compounds of formula I, wherein R1 is hydrogen or an amino-protecting radical and R2 and R3 are hydrogen or a hydroxy-protecting radical or taken together are a cyclic hydroxy-protecting radical.
公开号:SU1736342A3
申请号:SU884356869
申请日:1988-11-16
公开日:1992-05-23
发明作者:Фуджию Морио；Ишитсука Хидео；Мива Масанори；Умеда Исао；Иокосе Казутеру
申请人:Ф.Хоффманн-Ля Рош Аг (Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of new derivatives of 5-fluoro-cytidine, namely, 5-desokea-5-fluoro-cytidine of the general formula
-3 independently from each other radical, R4CO- or RsOCO- or RgSCO -, where Pd is alkyl C.-Cc-f, cycloalkyl
 4 C3
C3-C,
about
alkenyl, benzyl, etenphenyl, phenyl, optionally substituted by a chlorine atom or fluorine, a methyl group, one, two or three methoxy groups, a nitro group, an acetoxy group, a thiomethyl group, or E-phenylvinyl, 3-indolylmethyl, pyridyl , furyl, thienyl, naphthyl, piperonyl, nitrofuryl R, - alkyl C, | -Cg, benzyl
alkyl C-7-Cd, provided
R
C2-C4, which is one of R /, R2 and C
is not hydrogen, possessing antitumor properties.
A number of cytidine derivatives (1-5) are known, having for example 5-deoxy-5-fluorouridine, anti-tumor properties.
The purpose of the invention is to obtain new derivatives of 5-fluorocytidine, which have pharmacological advantages over known structural analogues of a similar effect.
The goal is achieved by the described method, in that the compound of the general formula
47
TLQ -Mffi
No
KV
where R7 and Kg are a protecting group, are reacted with a compound of the general formula
Xcor
four
where X is an OH group, COOR or halogen, a R has the indicated meanings, or with a compound of the general formula
.
where hat r "
0
halogen atom,
radical or where
R and Rg have the indicated 5 values, followed by
removal of protective groups. An example (known). A) In 1.5 ml of dimethylformamide, mg of 5-deoxy-5-fluoro-cytidine, 35 mg of tert-butyldimethylsilyl-chloride and mg of imidazole are dissolved. The mixture is stirred for 18 hours at room temperature under a nitrogen atmosphere. Then the reaction mixture 5 is poured into water and extracted with ethyl acetate. The extract was washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, to give 31 mg of 2 (, 3 / -bis-0- - (tert-butyldimethylsilyl) 5-deoxy-5-fluorocytidine, (mass spectrometry 73 +).
E). A solution of 90 mg of 5'-deoxy-5-fluorocytidine, дина mg of toluenesulfonic acid para-monohydrate and 9 HL μl of 2,2-dimethoxypropane in 10 ml of acetone is stirred for 1.5 hours at room temperature, 900 mg of sodium hydrogen carbonate are added to the solution and the mixture is stirred for k hours at room temperature. The precipitate is filtered off and washed with acetone. The combined filtrate is concentrated under reduced pressure. The residue is purified by column chromatography over silica gel (dichloromethane-methanol) to obtain 570 mg of 5-deoxy-5 Fluoro-2, 3 -0-isopropylideticine, mass spectroscopy 286 (Wi4), m.p. picrate 1b9 171 ° C. Example 1, A. In 150 ml of dichloromethane, 9.6 g of 2, 3-bis- -0- (tert-butyldimethylsilyl) -5-deoxy 5 fluorocytidine, prepared according to the well-known example (A), 3, are dissolved; 8 g of anhydrous 5-n-butyric acid in 2.93 g of f-dimethylaminopyridine. The mixture is stirred overnight, then washed with water, dried over anhyd. 5
0
sodium sulfate and concentrated under reduced pressure to obtain 9.75 g of p-butyryl-2 C -bis-O- - (tert-butyldimethylsilyl) -5 -deoxy-5 fluorocytidine, mass spectroscopy 544 (MH4).
B, The reaction product of example 1 (A) (9.75 g) is dissolved in Ј0 ml of tetrahydrofuran containing 80 mmol of fluoride Q 316 (MN)
stirred for 18 hours at room temperature. After removing the solvent, the residue is purified on silica gel column chromatography to obtain colorless crystals of 420 mg of N-butyryl-5 depsy-5-fluorocytidine, mp, 15b-157 ° C, mass spectroscopy
addition tetrabutylammonium. The reaction mixture is stirred for 1.5 hours at room temperature. After removing the solvent under reduced pressure, the residue is purified by column chromatography over silica gel (ethyl acetate - methanol), followed by recrystallization from methanol to obtain 4.5 g
15
Example 44 A. A. In 50 ml of dry pyridine, 4.9 g of 5-deoxy-5-fluorocytidine and 5.58 ml of trimethylsilyl chloride are dissolved. The mixture was stirred for 2 hours. To the reaction mixture was added 2.09 ml of chloroitomurate ethyl ester. After stirring the mixture for 2.5 hours, pyridine is evaporated at
M-butyryl-5-deoxy-5-fluorocytidine, 20 under reduced pressure. The balance is stripped, pl. 15b-157 ° C, mass spectroscopy 316 (MN).
The following compounds were prepared in a manner similar to Example 1 (Table 1).
Example 4 A. 14.19 g of 2,3-bis-0- (tert-butyldimethylsilyl) -5 -deoxy-5-fluorocytidine, prepared according to the known example (A), is dissolved in 150 ml of dry pyridine. While stirring, 3, Ј4 g of n-butyric acid chloride are added dropwise to the solution. The reaction mixture is stirred overnight. Pyridine is removed under reduced pressure and the residue is partitioned between water and ethyl acetate. The ethyl acetate layer is washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue is purified by column chromatography over silica gel (n-hexane-ethyl acetate) to give N-butyryl--2, 3 -bis-0- (tert-butyldimethylsilyl) -51-deoxy-5-fluorocytidine (25.82 d).
B, The reaction product from example 4 (A) is treated in the same manner as in example 1 (B) to obtain § colored crystals of K-butyryl-deoxy-5-fluorocytidine.
The following compounds were prepared in a manner similar to Example 4 (Table 2).
Example 43. In 20 ml of 75% aqueous dioxane, 735 mg of 5-deoxy-5-fluorocytidine and 1.04 g of butyric anhydride are dissolved. Mixture
then separated between water and ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulfate and concentrated.
25 under reduced pressure. To the residue was added 5 g of citric acid and 80 ml of methanol. The mixture is stirred for 1 hour. After removing the solvent under reduced pressure, the residue is purified by column chromatography over silica gel (methanol-dichloromethane), followed by recrystallization from dichloromethane, to obtain 2.66 g 5; dezok (ethylthio) -carbonyl 5 fluoro-35 tidine, so pl. 138-139 ° C (decomp.), Mass spectroscopy 334 (MN),
B. To a stirred solution of 1 g of 5-deoxy-5 fluoro-2, 3 -0-isopropyl, dentsitidine, obtained by a known example, in 8 ml of pyridine are added, at 0 ° C, 365 µl of ethyl ether of chlorothiopuric acid, and then a mixture stirred at room temperature overnight. The reaction mixture is concentrated under reduced pressure and the residue is partitioned between ethyl acetate and water. The organic layer is washed with sodium bicarbonate solution and
50 with water and dried over anhydrous sodium sulfate. After removal of the solvent, the residue is purified by column chromatography over silica gel (CHCl-j) to obtain 510 mg of 555-deoxy-M-C (ethylthio) -carbonyl-5-fluoro-2, 3 -0-isopropyl udentium, "mass spectroscopy 374 (MH +). g
B. To the solution of the reaction product from example 44 (B) (150 mg) in 50% water

63426
stirred for 18 hours at room temperature. After removing the solvent, the residue is purified on silica gel column chromatography to obtain colorless crystals of 420 mg of N-butyryl-5 depsy-5-fluorocytidine, mp, 15b-157 ° C, mass spectroscopy
316 (PL)
Example 44 A. A. In 50 ml of dry pyridine, 4.9 g of 5-deoxy-5-fluorocytidine and 5.58 ml of trimethylsilyl chloride are dissolved. The mixture was stirred for 2 hours. To the reaction mixture was added 2.09 ml of chloroitomurate ethyl ester. After stirring the mixture for 2.5 hours, pyridine is evaporated at
then separated between water and ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulfate and concentrated.
5 under reduced pressure. To the residue was added 5 g of citric acid and 80 ml of methanol. The mixture was stirred for 1 hour. After removing the solvent under reduced pressure, the residue was purified by column chromatography over silica gel (methanol-dichloromethane), followed by recrystallization from dichloromethane, to obtain 2.66 g 5; deloc- (ethylthio) -carbonyl 5 fluoro-5 tidine, so pl. 138-139 ° C (decomp.), Mass spectroscopy 334 (MN),
B. To a stirred solution of 1 g of 5-deoxy-5 fluoro-2, 3 -0-isopropylidenecytidine, obtained by a known example, in 8 ml of pyridine, at 0 ° C, add 365 µl of ethyl ether of chlorothiouramic acid, and then the mixture stirred at room temperature overnight. The Fe5 mixture is concentrated under reduced pressure and the residue is partitioned between ethyl acetate and water. The organic layer is washed with sodium bicarbonate solution and
0 with water and dried over anhydrous sodium sulphate. After removal of the solvent, the residue is purified by column chromatography over silica gel (CHCl-j) to obtain 510 mg of 55-deoxy-M-C (ethylthio) -carbonyl-5- -fluoro-2, 3 -0-isopropyl udientitin, ", mass spectroscopy 374 (MH +). g
B. To a solution of the reaction product from example 44 (B) (150 mg) in 50% water- (tert-butyldimethylsilyl) -5-deoxy-5-fluorocytidine, obtained according to the well-known example (A), and 0, 80 g
, 4-dimethylaminopyridine. After the mixture was stirred for 12 hours at room temperature, the pyridine was evaporated under reduced pressure. Then the residue is treated, as in JQ measure 48, to obtain. 0.55 g of 5-deoxy-5-fluoro-I - (3 Furoyl) -cytidine, m.p. 173,174 ° C (ethanol), 340 (MN) mass spectroscopy.
The following compounds are obtained by
15 in a manner similar to Example 50 (Table 5).
20
Dowex 50 (H +) (150 mg) is added to ethanol, the mixture is then heated at 50-60 ° C with stirring for 4 hours, the Dowex 50 is filtered off and the filtrate is concentrated to dryness under reduced pressure. The residue is purified by column chromatography over silica gel (CHCF3 - acetone), followed by recrystallization from dichloromethane, to obtain 5 deoxy-M - ((ethylthio) -carbonyl-5 fluorocytidine, t, melting point 138-139 ° C (decomp.), Mass spectroscopy 334 (MN).
The following compounds were prepared in a manner similar to Example 44 (Table 3).
Example 48 A solution of 0.42 g of piperonyl acid in 5 ml of dry acetonitrile containing 0.36 ml of triethylamine is treated with 0.37 ml of chlorophosphoric acid diethyl ether for 1 hour. To the reaction mixture are added 2, 3-bis-0- (tert-β-butyldimethylsilyl) -deoxy-5 Fluoro 25 cytidine (1.0 g) obtained by the known example (A), 0.36 ml of triethylamine and 0.05 g of 4 dimethylaminopiridine. After stirring the mixture for 12 hours at room temperature, the acetonitrile is evaporated under reduced pressure. The residue is partitioned between water and diethyl ether. The organic layer is washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting powder was dissolved in 6.3 ml of tetrahydrofuran containing 1.65 g of tetrabutylammonium fluoride and the reaction mixture was stirred for 1 hour. After removing the solvent under reduced pressure, the residue was purified by column chromatography over
silica gel (isopropanol-dichloromethane, oht, tan), followed by recrystallization-45 ° C with 2.5 ml of ammonium hydroxide to kNII. HNRHRHPPNTMmSplashtAn Example 57. A. To a stirred solution of 24.5 g of 5-deoxy-5-α-fluorouridine in 150 ml of dry pyridine is added dropwise 2.5 ml of benzoyl chloride over 10 minutes at 0 ° C and the mixture is stirred for 5 hours at room temperature. After removal of pyridine under reduced pressure, the residue is divided into parts between water and ethyl acetate. The organic layer is washed with a saturated solution of sodium bicarbonate and water, dried over anhydrous sodium sulfate and concentrated, and concentrated under reduced pressure. The residue is recrystallized from ethyl acetate together with n-hexane to obtain 9 g of 2 3 -di-O-benzoyl-5-deoxy-5
e-fluorouridine, mass spectroscopy 455 (MP).
B, To a mixture of 0.8 ml of N-methylimidazole and 0.28 ml of phosphoryl chloride in 20 ml of acetonitrile, 500 mg is added.
40 2 /, 3 -di-0-benzoyl-5-dizoxy-5-α-fluorouridine obtained at 0 ° C. After stirring the reaction mixture for 1.5 hours at room temperature, the mixture is added at
Cho,
lysing from ethyl acetate to obtain 0.5 g of 5-deoxy-5-fluoro-H-pi-peronyl-cyloidine, m.p. 12 - 125 ° C, mass spectroscopy 39 (MN), The following compound is obtained by the method similar to example 48 (table. B)
nor, and then the mixture is stirred for 1 h at room temperature. Acetonitrile and ammonia are removed under reduced pressure. The residue was acidified with a 1N HCl solution, and then extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
After that, the mixture is stirred for 1 hour at room temperature. Acetonitrile is removed and the ammonia is removed under reduced pressure. The residue was acidified with a 1N HCl solution, and then extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulphate and concentrated under reduced pressure.
Example 50. 0.355 g of 3-furancar - $ L pressure is dissolved in 5 l of dry pyridine. The residue was recrystallized with a boronic acid and 0.96 g of 2,4,6-tri-yarn from ethyl acetate to give isopropyl benzenesulfonyl chloride. 155 mg of 2, 3 -di-O-benzoyl-5-dezoks. The mixture was stirred for an hour. C-5-fluorocytidine, m. pl. 192-194 ° C. 1.0 g of 2,3-bis-0-mass spectroscopy 476 (MHtNa) 4 was added to the mixture.
- (tert-butyldimethylsilyl) -5-deoxy-5-fluorocytidine, obtained by the well-known example (A), and 0.80 g
4-dimethylaminopyridine. After the mixture was stirred for 12 hours at room temperature, the pyridine was evaporated under reduced pressure. Then the residue is treated as in example 48 to obtain. 0.55 g of 5-deoxy-5-fluoro-I - (3 Furoyl) -cytidine, m.p. 173,174 ° C (ethanol), 340 (MN) mass spectroscopy.
The following compounds are obtained by
5 in a manner similar to Example 50 (Table 5).
p ° g oo ooo ° C 2.5 ml ammonium hydroxide Example 57. A. To a stirred solution of 24.5 g of 5-deoxy-5-α-fluorouridine in 150 ml of dry pyridine are added dropwise 2.5 ml of benzoyl chloride for 10 min at 0 ° C and the mixture is stirred for 5 h at room temperature. After removal of pyridine under reduced pressure, the residue is divided into parts between water and ethyl acetate. The organic layer is washed with a saturated solution of sodium bicarbonate and water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue is recrystallized from ethyl acetate together with n-hexane to obtain 9 g of 2 3 -di-O-benzoyl-5-deoxy-5
-fluoridine, mass spectroscopy 455 (MP).
B, To a mixture of 0.8 ml of N-methylimidazole and 0.28 ml of phosphoryl chloride in 20 ml of acetonitrile, 500 mg is added.
2 /, 3-di-0-benzoyl-5-dizoxy-5-α-fluorouridine obtained at 0 ° C. After stirring the reaction mixture for 1.5 hours at room temperature, the mixture is added at
Cho,
п ° г о сооо, ° С 2.5 ml of ammonium hydroxide. I am a nuclear magnetic resonance generator, then the mixture is stirred for 1 h at room temperature. Acetonitrile and ammonia are removed under reduced pressure. The residue was acidified with 1N HCl solution, and then extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
pressure. The residue is recrystallized from ethyl acetate to obtain 155 mg of 2, 3-di-O-benzoyl-5-deoxy-5-fluorocytidine, m.p. 192-194 ° C, mass spectroscopy 476 (MHtNa) 4.
Example 52 A. To ice-cooled acetic anhydride (0.57 m is added dropwise 286 µl of 99% formic acid. The solution is stirred for 15 minutes at 0 ° C and for 50 minutes at 50 ° C and then cooled to 0 ° C. To the solution was added 73 mg of 2,3-bis-0- (tert-butyldimethylsilyl) -5-deoxy-5-fluorocytidine, prepared according to the well-known example (A), in 5 ml of dry pyridine at OV, The reaction mixture is stirred for 10 minutes at 0 ° C and for 26 hours at room temperature. After removing the solvent under reduced pressure, the residue is divided into parts water and ethyl acetate. The organic layer is washed with a saturated solution of sodium bicarbonate and water, and then dried over anhydrous sodium sulfate. The ethyl acetate is evaporated under reduced pressure and the residue is purified by column chromatography over silica gel (n-hexane-ethyl acetate), which follows recrystallization from a mixture of n-hexane and ethyl acetate to obtain mg 2,3 -bis-0- - (tert-butyldimethylsilyl) 5-deoxy-5-fluoro-K-formylcytidine, t, mp, 188 ° C ( .), mass spectroscopy 502 (MH4),
B. The reaction product from Example 58 (A) is treated in the same way as in Example 1 (B) to obtain amorphous 5g-dezonL powder: and -5 fluoro-1 $ 4-formylcytidine, mass spectroscopy 27 (MI4) ,
Example 59. mg 5-deoxide 5 fluorocytidine is dissolved in 5 ml of dry pyridine. 130 µl of benzoyl chloride is added to the solution with stirring at 0 ° C. The reaction mixture is stirred for 1 h at 0 ° C. After removing the solvent under reduced pressure, the residue is purified by column chromatography over silica gel (dichloromethane-methanol, followed by recrystallization from ethyl acetate, to obtain 51 mg of colorless crystals of Z-O-benzoyl-5-deoxy-5 Fluorcytidine, mp, mass spectroscopy 350 (PL)
Example 60. 35 mg of the product of Example 59 are dissolved in 0.5 ml of dry pyridine. 13.8 µl of trimethyl chloride are added to the solution.
tilsilil. After stirring for 2 hours at room temperature, 12.6 µl of benzoyl chloride is added. The reaction mixture is stirred for 1 hour. After removing the solvent under reduced pressure, the residue is dissolved in 0.5 ml of dry methanol. 15 mg of potassium carbonate is added to the solution and the reaction mixture is stirred for 30 minutes at 0 ° C. After removal of the solvent under reduced pressure, the residue is partitioned between water and ethyl acetate. The organic layer is dried over anhydrous magnesium sulphate and concentrated under reduced pressure. The residue is purified by column chromatography over silica gel (dichloromethanemethanol) to obtain 15 mg of N, 3 -0-dibenzoyl-5-deoxy-5-α-fluorocytidine amorphous powder, mass spectroscopy W (MH).
Example 61 In 5 ml of dry pyridine, mg of 5-deoxy-5-fluorocytidine, 00 µl of benzoyl chlorine and 122 mg of A-dimethyl-aminopyridine are dissolved. After stirring for 3 hours at room temperature, pyridine is removed under reduced pressure. The residue is partitioned between ethyl acetate and water. The ethyl acetate layer is dried over magnesium sulfate and concentrated under reduced pressure. The residue is recrystallized from methanol to obtain 280 mg of -0.3-0-β-tribenzoyl-5-deoxy-5 fluorocytidine, m.p. C, mass spectroscopy 558 (MN).
The antitumor activities of the proposed compounds are as follows.
Antitumor Tests against Sarcoma 180.
Sarcoma 180 cells (2U1 Ob cells are implanted subcutaneously in mice (20-22 grams) on day zero. The compounds of the invention are administered daily orally from day to day inclusive. Animals are sacrificed on Day 1 and the tumors are excised and weighed. Percentage the inhibition of tumor growth presented in Table 6 is calculated by the formula
(1 - T / C) K100,
where T is the weight of the tumors from the treated group,
C - the weight of tumors from the control group.
Antitumor test against fibrosarcoma Metha A,
 Metha A fibrosarcoma cells (cells) are implanted subcutaneously in mice (21-22 g), Metha A fibrosarcoma test and the percentage of tumor growth inhibited is calculated according to a method similar to that of Sarcoma 180. The results are presented in Table. 7
A comparative study of the antitumor activity of the characteristic compound (Example 3) of the invention together with 5 / deoxy-5 Fluorouridine is carried out according to a method similar to that of the antitumor test against Metha A. fibrosarcoma. The results of this experiment and fecal observation on the 8th day are presented in Table. 8 and show that the compound of Example 3 is more potent for antitumor activity, but less toxic than 5-deoxy-5 fluorouridine. In the same experiment, the compound of Example 3 does not cause diarrhea (diarrhea), which is a dose-limiting factor of 5 deoxy-5-fluorouridine.
Comparative antitumor test against Lewis lung carcinoma.
The antitumor activity of the representative compound (Example 1) of the invention is compared with that of 5-deoxy-5 fluorouridine and the drug combination, UFT (tegafur: 1: 4 uracy). Mice are infected subcutaneously with Lewis lung carcinoma (106 cells) on day zero.
The compounds are administered daily 14 times, starting from the first day by the oral route. The effective dose (ED50) at which tumor growth is inhibited by 50%, as well as toxic doses are determined. Therapeutic indices (toxic doses / / ED5o) obtained from the experiments are presented in Table. 9. The compound of the invention has higher therapeutic indices than typical prodrugs of 5-fluorouracil, 5-deoxy-5-fluorouridine and UFT. The compound causes less toxicity of the intestinal tracts (diarrhea) and immune-susceptible organs (thymus and bone marrow). These data indicate that the target compound has a higher safety potential.
Comparative antitumor test against Sarcoma 180 fibroQ sarcoma Metha A and fibrosarcoma UV2237.
The antitumor efficacy of the characteristic compound (Example 1) of the invention in three models of ripened
r (murine) tumors are compared to 5g-deoxy-5 fluorouridine and 5-deoxy-5-fluorocytidine. Mice are charged subcutaneously with Sarcoma 180 with Metha A fibrosarcoma and vibrosarcoma
0 2237 on the zero day. Mice were then orally administered daily up to 7 times daily, starting on the first day. Efficacy is expressed as therapeutic indices (Eduyoks / EDsd),
5 measured on the 14th day after tumor infusion, where EDco is the dose showing maximum tumor growth inhibition. The results obtained from the experiments
- are presented in table. ten.
The acute toxicity () of the proposed compound (Examples 1, 5, 9, 24, 34, 46 and 47) is studied by means of "1 oral administration to mice. The corresponding LD50 values obtained from the experiments are more than 2,000 mg / kg.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining derivatives of 5-deoxy-5-fluorocytidine total FORNI,
 GU
M NQR3
where Rj, RЈ and R}, independently of Groug, are the radical .CO- or RSOCO- or, where R (. is alkyl cycloalkyl to, Cj is alkenyl, benzyl, phenethyl, phenyl, possibly substituted by chlorine or fluorine, methyl group , one or two or three methoxy groups, a nitro group, ace 1317363 2
sing, with a thiomethyl group, phenyl vinyl, 3-indolylmethyl, furyl, thienyl, naphthyl, pietrophuryl, R-aryl Rg-alkyl, when conditional from Cc, RZ.M R-5 is not natural, it is distinguished that the compound is common
Wg oV
Chu
,
gd not
five
gd
U il
gd
15 gd
with gr
14
where RA is a protective group, is reacted with a compound of the general formula
 XCORjj.,
where X is a OH group, -ССЖД. or halogen,
R4 has the indicated meanings, or with a compound of the general formula
HalCORj,
where NaЈ is halogen,
Ra is a radical, or, 5 where Ry and
Rg have the indicated values followed by removal of the protecting groups.
Table 1
2-COCH3
QCHj
3CQ- (oWllj
OCH3
-eo ("5 (Kj -eoicnibCHj
with
-coWH fflj
-SUFF
-soin (sadg
157 - 159 Ethyl alcohol288
170-171 Ethylacetate-IO
new air
table 2
106-107
Ethyl ether
-ME-372
386 is obtained as an amorphous powder.
Methanol
Also
512
316 is obtained as an amorphous powder.
 five
1736342 6
Continuation of table 2
2,
W-WTC 11-C8-
12
-co
13-CO
14-SO-SKO
15
21
but
22 -GO- ©
N.
III: E :::: J:
Also
330
Ethylacetate - 314 Tatmetanol
Receives - 356 s in the form of amorphous powder
Also
408
Receives - 364 s in the form of amorphous powder
Ethylate- 376 tat
16 / 1-165 Same
381
182-18 Methanol 38 decomposes
161-163 Methanol 368
166-167 Ethyl acetate- 379 tat
17
39
С ° Ч
ifO - (
17363 218
Continued table. 2
17S75 Methanol 370
167-168 CH2C12AOO
nineteen
 -coo№) 7enj
42
-sonsnea
119-120 Ethyl acetate- 302 ethyl ether
-CO (CH) 3CHN 150-151 Ztilacetate 330 -SOCH2CH (CH3) 2 142-143 Ditto 330
49 —OCOCH CH H 137-138 Ethyl acetate
51 -G
17363 “2
20 Continuation of table „2
107-109 Ethyl 402 ether
150-151 Methanol 380
Table 3
Table 4
314
Table 5
Obtained as an amorphous powder.
Ethanol Same
394
378 378
21
2 5 6
7 8
9 10 11 12 13 15
1736342
22
Continued table. five
2317363 2
Continuation of table 7
i;
iz ::: i:

0.8 1.5
1.5 3.0
0.8 1.5
1.5 3.0
1.5 3.0
1.5-3.0
1.5 3.0
1.5 3.0
1.5 3.0
1.5 3.0
1.3 2.6
1.5 3.0
1.5 3.0
17 60
42 42
56
64
-6
34
37 58
58 91
-13 -13
49 92
55 58
55 84
75 92
53 92
59 86
2k
ten
15
20
25
thirty
35
40
Table 8
25
Note, N is normal feces,
L - loose feces; D - diarrhe (diarrhea).
13
The EDU values of the compounds of example 1 of 5-deoxy-5-fluorouridine and UFT, measured on the day after infection with the tumor, are 0.15, 0.20 and 0.086 mmol / kg / day, respectively.
t
17363 2
26
s
Continued table. eight
Table 9
13
11.3
10.7
Table 10

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1736342A3|1992-05-23|Method of 5ъ-deoxy-5-fluorocytidine synthesis

---

FI93217C|1995-03-10|Process for the preparation of esters and amides of therapeutically active nucleoside derivatives

---

EP0354583B1|1993-11-03|DC-88A derivatives

---

KR100312445B1|2001-11-09|Producing process of trifluoromethylpyroloindolecarboxylic acid ester

---

SU1538893A3|1990-01-23|Method of producing n-deformyl-n/n,n-bis-|/distamycine hydrochloride

---

JPH069602A|1994-01-18|Intermediate of difluoro antiviral agent

---

IE64506B1|1995-08-09|Prodrugs of rapamycin

---

US20050020533A1|2005-01-27|Ceramide analogs, process for their preparation and their use as antitumor agents

---

IE921148A1|1992-10-21|Anti-tumor and anti-psoriatic agents

---

US4613666A|1986-09-23|Neplanocin A derivatives

---

AU593773B2|1990-02-22|New 6-substituted mitomycin analogs

---

EP0437469A1|1991-07-24|Nucleoside derivatives

---

EP0416605B1|1994-04-13|Novel oxetanocin derivatives and their salts as well as use thereof

---

JP2842640B2|1999-01-06|Solvates of β-lactam antibiotics

---

US4133964A|1979-01-09|α-Acetylenic derivatives of α-amino acids

---

Lee et al.1987|Antitumor agents. 86. Synthesis and cytotoxicity of. alpha.-methylene-. gamma.-lactone-bearing purines

---

SU1301831A1|1987-04-07|9a-methoxymitosan 7-substituted derivatives possessing antitumoral activity

---

SU795469A3|1981-01-07|Method of preparing uracyl derivatives

---

WO1996035431A1|1996-11-14|Derivatives of 2,3:4,6-di-o-isopropylidene-alpha-l-xylo-2-hexulofluranosonic acid

---

EP0303269A2|1989-02-15|2&#39;-Deoxy-5-fluorouridine derivatives, process for preparing the same and the use thereof

---

EP3478701A1|2019-05-08|Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use

---

SU735169A3|1980-05-15|Method of preparing cephalosporin derivatives

---

JPH01143878A|1989-06-06|Production of silicon azide

---

JP2805323B2|1998-09-30|2&#39;-Deoxy-5-fluorouridine derivative, method for producing the same, and antitumor agent containing the same as an active ingredient

---

US4190586A|1980-02-26|α-Acetylenic derivatives of α-amino acids

同族专利:

---

公开号 | 公开日

---

ZA888428B|1989-06-28|

---

EP0316704A3|1990-11-22|

---

ES2074429T3|1995-09-16|

---

HK1003114A1|1998-10-09|

---

AU2516888A|1989-05-25|

---

GR3017686T3|1996-01-31|

---

NZ226923A|1990-10-26|

---

EP0316704A2|1989-05-24|

---

NO171167B|1992-10-26|

---

NL300045I2|2002-01-02|

---

CN1033183A|1989-05-31|

---

CN1022688C|1993-11-10|

---

PT89009A|1988-12-01|

---

NO171167C|1993-02-03|

---

HUT48267A|1989-05-29|

---

FI885329A0|1988-11-17|

---

FI885329A|1989-05-18|

---

JPH01153696A|1989-06-15|

---

IS3412A7|1989-05-18|

---

IS1895B|2003-10-20|

---

CS274486B2|1991-04-11|

---

AT124951T|1995-07-15|

---

DK170893B1|1996-03-04|

---

DE10199027I1|2001-08-02|

---

YU47122B|1994-12-28|

---

DK640388A|1989-05-18|

---

DE10199027I2|2002-01-31|

---

DE3854148D1|1995-08-17|

---

NO2001013I2|2006-05-01|

---

LT2185B|1993-10-15|

---

EP0316704B1|1995-07-12|

---

YU209188A|1990-08-31|

---

LV5624A3|1994-05-10|

---

MC1992A1|1989-11-30|

---

NO885106L|1989-05-18|

---

PT89009B|1993-02-26|

---

CS747588A2|1990-09-12|

---

IL88363D0|1989-06-30|

---

KR890008162A|1989-07-10|

---

NO885106D0|1988-11-16|

---

FI89804C|1993-11-25|

---

HU199866B|1990-03-28|

---

DK640388D0|1988-11-16|

---

US4966891A|1990-10-30|

---

LU90769I2|2001-07-02|

---

DZ1270A1|2004-09-13|

---

UA19333A|1997-12-25|

---

CA1327358C|1994-03-01|

---

JPH0678350B2|1994-10-05|

---

FI89804B|1993-08-13|

---

AU619220B2|1992-01-23|

---

MX173347B|1994-01-03|

---

AR247217A1|1994-11-30|

---

PH25641A|1991-08-21|

---

MX13836A|1993-10-01|

---

NL300045I1|2001-08-01|

---

IE883430L|1989-05-17|

---

KR970000241B1|1997-01-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3404144A|1965-12-23|1968-10-01|Research Corp|1-beta-d-arabinofuranosyl-5-fluorocytosine compounds|

---

GB1379410A|1971-06-08|1975-01-02|Upjohn Co|1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines|

---

JPS5422991B2|1976-06-11|1979-08-10|

---

US4071680A|1976-12-20|1978-01-31|Hoffmann-La Roche Inc.|5'-Deoxy-5-fluoropyrimidine nucleosides|

---

CH633810A5|1978-01-01|1982-12-31|Hoffmann La Roche|Novel nucleosides and process for their preparation|

---

FR2528311B1|1982-06-14|1985-06-14|Synthelabo|PURIC AND PYRIMID BASED XYLOSIDE AND LYXOSIDE PHARMACEUTICAL COMPOSITIONS|

---

JPH0468320B2|1984-11-05|1992-11-02|Wakunaga Seiyaku Kk|US6258360B1|1989-05-04|2001-07-10|Igen International, Inc.|Prodrugs activated by targeted catalytic proteins|

---

US5527782A|1990-03-13|1996-06-18|AcicInc.|5-halo-2,3'-O-cyclocytidines|

---

TW254946B|1992-12-18|1995-08-21|Hoffmann La Roche|

---

AU671491B2|1992-12-18|1996-08-29|F. Hoffmann-La Roche Ag|N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines|

---

US5476932A|1994-08-26|1995-12-19|Hoffmann-La Roche Inc.|Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives|

---

NZ330360A|1997-06-02|1999-03-29|Hoffmann La Roche|5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents|

---

EP0882734B1|1997-06-02|2009-08-26|F. Hoffmann-La Roche Ag|5'-Deoxy-cytidine derivatives|

---

US6005098A|1998-02-06|1999-12-21|Hoffmann-La Roche Inc.|5'deoxycytidine derivatives|

---

US20080113025A1|1998-11-02|2008-05-15|Elan Pharma International Limited|Compositions comprising nanoparticulate naproxen and controlled release hydrocodone|

---

JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|

---

US20010051348A1|2000-01-28|2001-12-13|Lee Chee Wee|Novel ligands and methods for preparing same|

---

SE0102764D0|2001-08-17|2001-08-17|Astrazeneca Ab|Compounds|

---

US6774758B2|2002-09-11|2004-08-10|Kalyan P. Gokhale|Low harmonic rectifier circuit|

---

GB0226930D0|2002-11-19|2002-12-24|Astrazeneca Ab|Chemical compounds|

---

CA2525973A1|2003-05-20|2004-12-09|Aronex Pharmaceuticals, Inc.|Combination chemotherapy comprising capecitabine and a liposomal platinum complex|

---

EP1706414B1|2003-12-22|2008-07-23|F.Hoffmann-La Roche Ag|Process for fluorocytidine derivatives|

---

WO2005080360A1|2004-02-18|2005-09-01|Astrazeneca Ab|Compounds|

---

AT426597T|2004-02-18|2009-04-15|Astrazeneca Ab|BENZAMID DERIVATIVES AND THEIR USE AS GLUCCOINASE-ACTIVATING AGENTS|

---

CN100383128C|2004-02-23|2008-04-23|上海迪赛诺医药发展有限公司|Ramification of N-carbethoxy cytosine and preparation method and application|

---

TW200600086A|2004-06-05|2006-01-01|Astrazeneca Ab|Chemical compound|

---

KR101061850B1|2004-09-08|2011-09-02|삼성전자주식회사|Thin film transistor array panel and manufacturing method thereof|

---

GB0421294D0|2004-09-24|2004-10-27|Angiogene Pharm Ltd|Bioreductively-activated prodrugs|

---

GB0423043D0|2004-10-16|2004-11-17|Astrazeneca Ab|Compounds|

---

US7700640B2|2004-10-16|2010-04-20|Astrazeneca Ab|Process for making phenoxy benzamide compounds|

---

ES2364495T3|2005-02-03|2011-09-05|The General Hospital Corporation|METHOD TO TREAT CANCER RESISTANT TO GEFITINIB.|

---

NO322682B1|2005-03-18|2006-11-27|Clavis Pharma Asa|Use of gemcitabine derivatives for the preparation of oral dosage forms in cancer treatment, as well as such oral dosage forms|

---

AU2006228581A1|2005-04-01|2006-10-05|F. Hoffmann-La Roche Ag|Method for administration of capecitabine|

---

JP2008542247A|2005-05-24|2008-11-27|アストラゼネカアクチボラグ|2-Phenyl substituted imidazole [4,5B] pyridine / pyrazine and purine derivatives as glucokinase modulators|

---

TW200714597A|2005-05-27|2007-04-16|Astrazeneca Ab|Chemical compounds|

---

EP2027113A1|2005-07-09|2009-02-25|AstraZeneca AB|Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes|

---

EP2305674A1|2005-07-09|2011-04-06|AstraZeneca AB|Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes|

---

US20110053910A1|2005-07-09|2011-03-03|Mckerrecher Darren|2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes|

---

CN100569790C|2005-07-15|2009-12-16|上海奥锐特国际贸易有限公司|Synthetic N 4The method of-acyl group-5 ＇-deoxidation-5-fluorcytidines|

---

JP2009501734A|2005-07-21|2009-01-22|ヌボ・リサーチ・インコーポレイテッド|How to treat cancer|

---

US9202182B2|2005-08-11|2015-12-01|International Business Machines Corporation|Method and system for analyzing business architecture|

---

US20070104721A1|2005-11-04|2007-05-10|Wyeth|Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272|

---

TW200738621A|2005-11-28|2007-10-16|Astrazeneca Ab|Chemical process|

---

US20080085310A1|2006-10-06|2008-04-10|Maria Oksana Bachynsky|Capecitabine rapidly disintegrating tablets|

---

TW200825063A|2006-10-23|2008-06-16|Astrazeneca Ab|Chemical compounds|

---

TW200825060A|2006-10-26|2008-06-16|Astrazeneca Ab|Chemical compounds|

---

CN100425617C|2006-10-31|2008-10-15|浙江海正药业股份有限公司|Fluoropyrimidine compound carbalkoxylation method|

---

RU2009121756A|2006-12-21|2011-01-27|Астразенека Аб |NEW CRYSTAL COMPOUND USEFUL AS A GLUCOKINASE ACTIVATOR |

---

ITMI20070435A1|2007-03-05|2008-09-06|Innovate Biotechnology Srl|2 ', 3'-DI-O-acyl-5-FLUORONUCLEOSIDI|

---

EP2137201A2|2007-04-20|2009-12-30|Dr. Reddy's Laboratories Ltd.|Process for preparing capecitabine|

---

EP2164856A1|2007-06-01|2010-03-24|Synthon B.V.|Processes related to making capecitabine|

---

WO2009042064A2|2007-09-21|2009-04-02|Nektar Therapeutics Al, Corporation|Oligomer-nucleoside phosphate conjugates|

---

US8022216B2|2007-10-17|2011-09-20|Wyeth Llc|Maleate salts of -N-{4-[3-chloro-4-anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4--2-butenamide and crystalline forms thereof|

---

EP2225566A1|2008-01-03|2010-09-08|Plus Chemicals S.A.|Process for the preparation of capecitabine|

---

SG191676A1|2008-06-17|2013-07-31|Wyeth Llc|Antineoplastic combinations containing hki-272 and vinorelbine|

---

AR072900A1|2008-08-04|2010-09-29|Astrazeneca Ab|THERAPEUTIC AGENTS DERIVED FROM PIRAZOLO [3,4-D] PYRIMIDINE|

---

EP3175853A1|2008-08-04|2017-06-07|Wyeth LLC|Antineoplastic combinations of neratinib and capecitabine|

---

EP2370414A4|2008-12-02|2012-11-14|Reddys Lab Ltd Dr|Preparation of capecitabine|

---

WO2010063080A1|2008-12-05|2010-06-10|Commonwealth Scientific And Industrial Research Organisation|Amphiphile prodrugs|

---

CN101787066B|2009-01-23|2013-07-31|高峰|Cytarabine derivatives and purposes thereof in resisting cancers and tumors|

---

GB0902406D0|2009-02-13|2009-04-01|Astrazeneca Ab|Crystalline polymorphic form|

---

GB0902434D0|2009-02-13|2009-04-01|Astrazeneca Ab|Chemical process|

---

BRPI1012699A2|2009-04-06|2016-03-22|Wyeth Llc|neratinib treatment regimen for breast cancer|

---

AR076220A1|2009-04-09|2011-05-26|Astrazeneca Ab|DERIVATIVES OF PIRAZOL [4,5 - E] PYRIMIDINE|

---

AR076221A1|2009-04-09|2011-05-26|Astrazeneca Ab|DERIVED FROM PIRAZOL [4,5-E] PYRIMIDINE AND ITS USE TO TREAT DIABETES AND OBESITY|

---

CN101875680B|2009-04-28|2012-07-25|上海信旗医药科技有限公司|Nucleoside compound, preparation method and application thereof|

---

WO2011010967A1|2009-07-23|2011-01-27|Scinopharm Taiwan Ltd.|Process for producing flurocytidine derivatives|

---

HUE040107T2|2010-03-12|2019-02-28|Genzyme Corp|Combination therapy for treating breast cancer|

---

AU2013243955B2|2012-04-02|2018-02-22|Modernatx, Inc.|Modified polynucleotides for the production of oncology-related proteins and peptides|

---

AU2013243949A1|2012-04-02|2014-10-30|Moderna Therapeutics, Inc.|Modified polynucleotides for the production of biologics and proteins associated with human disease|

---

JP6666147B2|2012-09-26|2020-03-13|エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト|Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use|

---

JP2015536954A|2012-11-07|2015-12-24|ズカイ スオ|Substituted gemcitabine arylamide analogues|

---

EP2968382B1|2013-03-15|2018-03-07|Nucorion Pharmaceuticals, Inc.|Substituted gemcitabine bicyclic amide analogs and treatment methods using same|

---

US10138507B2|2013-03-15|2018-11-27|Modernatx, Inc.|Manufacturing methods for production of RNA transcripts|

---

EP3041938A1|2013-09-03|2016-07-13|Moderna Therapeutics, Inc.|Circular polynucleotides|

---

AU2014315287A1|2013-09-03|2015-03-12|Moderna Therapeutics, Inc.|Chimeric polynucleotides|

---

CN103450301B|2013-09-09|2015-09-09|南通大学|Farnesyl thiosalicylic acid-nucleosides conjugate, its preparation method and medicinal use thereof|

---

US10323076B2|2013-10-03|2019-06-18|Modernatx, Inc.|Polynucleotides encoding low density lipoprotein receptor|

---

JP6950972B2|2016-06-28|2021-10-20|セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ|Compositions and Methods for the Treatment of Cancer|

---

EP3565549B1|2017-01-09|2022-03-09|Shuttle Pharmaceuticals, Inc.|Selective histone deacetylase inhibitors for the treatment of human disease|

---

BR112019022470A2|2017-04-26|2020-05-12|I. Kalman Thomas|COMPOUND, COMPOSITION, AND, METHOD FOR TREATING AN INDIVIDUAL WITH CANCER.|

---

US10435429B2|2017-10-03|2019-10-08|Nucorion Pharmaceuticals, Inc.|5-fluorouridine monophosphate cyclic triester compounds|

---

WO2019143860A1|2018-01-19|2019-07-25|Nucorion Pharmaceuticals, Inc.|5-fluorouracil compounds|

---

CN109651467A|2019-01-15|2019-04-19|齐鲁天和惠世制药有限公司|A kind of capecitabine impurity and preparation method thereof|

---

WO2022020811A1|2020-07-24|2022-01-27|Strand Therapeutics, Inc.|Lipidnanoparticle comprising modified nucleotides|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

EP87116926|1987-11-17|LV930507A| LV5624A3|1987-11-17|1993-06-08|Contribution to obtaining 5'-deoxy-5-fluorocytidine derivatives|

---

LTRP802A| LT2185B|1987-11-17|1993-07-20|THE 5'-DEOXY-5-FLUORCITIDINE DAILY RECEIPT|